Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2020

View Archived Issues

Metacrine reports phase I data on FXR agonist MET-642

Interim analysis update on remestemcel-L study in COVID-19 ARDS

Phase II study of BN-Brachyury in chordoma shows signs of clinical activity

Olinvacimab plus pembrolizumab shows clinical benefit in phase Ib study in mTNBC

DZD-4205 demonstrates efficacy in phase I/II JACKPOT8 study in PTCL

Discovery of new PDIA1 inhibitor with antitumor activity in models of multiple myeloma

Chiesi Farmaceutici divulges new P2X3 receptor antagonists

Sage Therapeutics synthesizes CYP46A1 inhibitors

Kallyope identifies new FFAR1 agonists

Korea Pharma describes JAK1 inhibitors

University of California, Oakland patents modified ZIVK-based products for cancer

Preliminary phase I/II data for ZN-c5 monotherapy in ER-positive/HER2-negative breast cancer

Triumeq shown to slow down progression of MND in mice

Tumors, metastases activate mTOR in different ways

Soricimed to explore utility of SOR-C13 for COVID-19

FDA approves Orgovyx for advanced prostate cancer

FDA issues EUA for Moderna's mRNA-1273 for COVID-19

Phase III studies of faricimab in DME meet primary endpoint

FDA issues complete response letter for inclisiran

Qu Biologics to evaluate potential of QBKPN to prevent and treat SARS-CoV-2 infection

XEN-496 shows comparable PK data to that of retigabine

Nanoform announces first human dosing with nanoformed drug

European Commission approves Palforzia to treat peanut allergy

LACEWING study of Xospata in FLT3mut+ AML does not meet primary endpoint

FDA approves Xpovio for multiple myeloma after at least one prior therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...